Abstract B7: Hypoxia-inducible factor 1 mediates thrombosis-associated cancer progression

• Published in: Cancer research (Chicago, Ill.) Ill.), 2013-02, Vol.73 (3_Supplement), p.B7-B7
• Main Authors: Evans, Colin E., Branco-Price, Cristina, Humphries, Julia, Wadoodi, Ashar, Saha, Prakash, Kim, Jung-whan, Belting, Mattias, Smith, Alberto, Johnson, Randall S.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.TIM2013-B7

Background. Cancer patients are up to 50 times more likely to suffer from lethal venous thromboembolism compared with non-cancer patients, but mechanisms that regulate the positive correlation between these conditions are unclear. Our primary aim was to test whether hypoxia within cells contained in the thrombus and adjacent vein leads to upregulation of hypoxia-inducible factor 1 (HIF1), which in turn stimulates the production of factors that mediate tumor growth and metastasis. Methods. Systemic or endothelial and myeloid HIF1 levels were altered (via administration of HIF1 agonist L-mimosine or via cre-Tie2 driven HIF1 deletion respectively) in established mouse models of thrombosis and breast cancer (inferior vena cava stenosis or polyoma middle T mutation driven by mouse mammary tumour virus respectively). Protein arrays were used to quantify the expression of 25 factors that regulate coagulation, thrombosis, and cancer progression. Adhesion and migration assays were used to characterise tumor and endothelial cell behaviour on thrombotic surfaces; while endothelial and tumor cell oxygen consumption rate was measured before and after thrombin treatment. Image analysis was also used to quantify intra-tumor thrombus formation. Results. Thrombus formation or upregulation of HIF1 increased the circulating expression of 10 factors that mediate tumor growth and remodelling including vascular endothelial growth factor (VEGF, 2±1 vs 1±0.2pg/ml in controls, n=6/group, P